Valuation: aTyr Pharma, Inc.

Market Cap 16.19M 14.46M 13.36M 12.11M 22.65M 1.54B 23.02M 161M 63.65M 805M 60.78M 59.48M 2.54B P/E 2026 *
-0.4x
P/E 2027 * -0.37x
Enterprise Value 16.19M 14.46M 13.36M 12.11M 22.65M 1.54B 23.02M 161M 63.65M 805M 60.78M 59.48M 2.54B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: aTyr Pharma, Inc.

1 day-2.88%
1 week-5.11%
Current month-45.51%
1 month-51.10%
3 months-65.12%
6 months-78.97%
Current year-78.92%
1 week 0.16
Extreme 0.16
0.18
1 month 0.16
Extreme 0.16
0.32
Current year 0.16
Extreme 0.16
1.11
1 year 0.16
Extreme 0.16
1.11
3 years 0.16
Extreme 0.16
7.29
5 years 0.16
Extreme 0.16
9.24
10 years 0.16
Extreme 0.16
90.94
Manager TitleAgeSince
Chief Executive Officer 54 2017-10-31
Director of Finance/CFO - 2026-09-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 54 2017-10-31
Chairman 59 2024-03-13
Director/Board Member 69 2019-06-27
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Other

Chief Financial Officer

325,592 0.3319%
10/1/26 Free

Chief Financial Officer

410,000 0.4180%
5/27/26 Buy

Founder

100,000 0.1020%
Change 5-day change 1-year change 3-year change Capi.($)
-2.88%-5.11%-82.90%-86.58% 16.19M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average -0.04%+1.66%+34.98%+118.14% 38.31B
Weighted average by Cap. +0.39%+2.73%+46.01%+142.83%

Financials

2026 *2027 *
Net sales - -
Net income -40.69M -36.33M -33.56M -30.42M -56.91M -3.86B -57.85M -404M -160M -2.02B -153M -149M -6.38B -42.92M -38.32M -35.4M -32.08M -60.02M -4.07B -61.02M -426M -169M -2.13B -161M -158M -6.73B
Net Debt - -
Projected Income Statement - Annual - aTyr Pharma, Inc.
Logo aTyr Pharma, Inc.
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
Employees
59
Date Price Change Volume
26-10-23 US$0.1651 -2.88% 1,300,886
26-10-22 US$0.1700 -1.33% 1,039,984
26-10-21 US$0.1723 -0.58% 1,234,629
26-10-20 US$0.1733 +0.93% 1,321,235
26-10-19 US$0.1717 -1.32% 2,109,645
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - aTyr Pharma, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
0.1651USD
Average target price
2.857USD
Spread / Average Target
+1,630.55%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - aTyr Pharma, Inc.
  1. Stock Market
  2. Stocks
  3. ATYR Stock